capricor.com (CAPR) - מקדם חוב לטווח ארוך להון

Capricor Therapeutics (CAPR) is developing unique cellular therapies for muscular dystrophy, supported by patent protection and a temporary advantage in clinical trials. However, a lack of profitability and dependence on capital make investments risky should the trials fail. This chart reflects the asset value fixed at 0.39, which complements the company's strategy to scale production and obtain FDA approvals.

This indicator assesses the financial stability of Capricor Therapeutics (CAPR) through the ratio of long-term liabilities to equity, determining the business's dependence on external borrowing. Analyzing the proportion of long-term debt to equity provides insight into the extent to which investments in robotic bioreactors for exosome production are funded by capital, which minimizes bankruptcy risks when scaling automated processes.